NEW YORK (GenomeWeb News) – The National Cancer Institute is continuing its support for a program under which cancer researchers can receive assistance in conducting validations of biomarker programs.
The NCI said yesterday that the goal of the Program for Rapid, Independent Diagnostic Evaluation, or PRIDE, is to help researchers advance biomarkers from the lab to clinically viable tests through cross-laboratory validation. The PRIDE program’s efforts include the development, refinement, and use of assays, reagents, methods, and tests.
The PRIDE program is part of the NCI’s Early Detection Research Network. The EDRN began in 2000 to help investigators with rapid evaluation of the reproducibility, portability, and precision of their technologies and biomarker assays. It will be supported by NCI for another year, according to Donald Johnsey of the NCI’s Division of Cancer Prevention.
More information about the PRIDE program can be found here.